• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

亚叶酸对甲氧苄啶-磺胺甲恶唑预防和治疗大鼠卡氏肺孢子虫肺炎能力的影响。

Effect of folinic acid on the capacity of trimethoprim-sulfamethoxazole to prevent and treat Pneumocystis carinii pneumonia in rats.

作者信息

D'Antonio R G, Johnson D B, Winn R E, van Dellen A F, Evans M E

出版信息

Antimicrob Agents Chemother. 1986 Feb;29(2):327-9. doi: 10.1128/AAC.29.2.327.

DOI:10.1128/AAC.29.2.327
PMID:3487285
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC176401/
Abstract

Daily administration of 1 mg of folinic acid to immunosuppressed rats with incipient or established Pneumocystis carinii pneumonia did not impair the capacity of trimethoprim-sulfamethoxazole to either prevent or treat this disease. These observations constitute the first experimental support for the use of folinic acid to prevent or control cytopenias that occur in patients with Pneumocystis carinii pneumonia who are under trimethoprim-sulfamethoxazole treatment.

摘要

对患有初期或已确诊卡氏肺孢子虫肺炎的免疫抑制大鼠每日给予1毫克亚叶酸，并不影响甲氧苄啶-磺胺甲恶唑预防或治疗该病的能力。这些观察结果为使用亚叶酸预防或控制接受甲氧苄啶-磺胺甲恶唑治疗的卡氏肺孢子虫肺炎患者出现的血细胞减少症提供了首个实验依据。

相似文献

1
Effect of folinic acid on the capacity of trimethoprim-sulfamethoxazole to prevent and treat Pneumocystis carinii pneumonia in rats.亚叶酸对甲氧苄啶-磺胺甲恶唑预防和治疗大鼠卡氏肺孢子虫肺炎能力的影响。
Antimicrob Agents Chemother. 1986 Feb;29(2):327-9. doi: 10.1128/AAC.29.2.327.
2
Resistance to trimethoprim-sulfamethoxazole in the treatment of Pneumocystis carinii pneumonia. Implication of folinic acid.甲氧苄啶-磺胺甲恶唑治疗卡氏肺孢子虫肺炎的耐药性。亚叶酸的影响。
Chest. 1984 Jul;86(1):149-50. doi: 10.1378/chest.86.1.149.
3
Effect of folic and folinic acid on cytopenia occurring during co-trimoxazole treatment of Pneumocystis carinii pneumonia.
Scand J Infect Dis. 1988;20(6):685-6. doi: 10.3109/00365548809035671.
4
Successful treatment and prevention of murine Pneumocystis carinii pneumonitis with 4,4'-sulfonylbisformanilide.用4,4'-磺酰双甲酰苯胺成功治疗和预防小鼠卡氏肺孢子虫肺炎。
Antimicrob Agents Chemother. 1986 Mar;29(3):509-10. doi: 10.1128/AAC.29.3.509.
5
Failure of trimethoprim-sulfamethoxazole in the therapy of recurrent Pneumocystis carinii pneumonia.复方新诺明治疗复发性卡氏肺孢子虫肺炎失败
Am Rev Respir Dis. 1982 Jun;125(6):762-5. doi: 10.1164/arrd.1982.125.6.762.
6
Limited effect of trimethoprim-sulfamethoxazole prophylaxis on Pneumocystis carinii.甲氧苄啶-磺胺甲恶唑预防对卡氏肺孢子虫的作用有限。
Antimicrob Agents Chemother. 1979 Sep;16(3):333-5. doi: 10.1128/AAC.16.3.333.
7
Pneumocystis carinii pneumonia: a problem revisited.卡氏肺孢子虫肺炎：一个重新审视的问题。
J Assoc Pediatr Oncol Nurses. 1984 Summer;1(3):16-23. doi: 10.1177/104345428400100306.
8
Efficacy of DL-alpha-difluoromethylornithine in a rat model of Pneumocystis carinii pneumonia.DL-α-二氟甲基鸟氨酸在卡氏肺孢子虫肺炎大鼠模型中的疗效。
Antimicrob Agents Chemother. 1988 Aug;32(8):1158-63. doi: 10.1128/AAC.32.8.1158.
9
Surfactant phospholipids and lavage phospholipase A2 in experimental Pneumocystis carinii pneumonia.实验性卡氏肺孢子虫肺炎中的表面活性物质磷脂和灌洗磷脂酶A2
Am Rev Respir Dis. 1986 Sep;134(3):526-31. doi: 10.1164/arrd.1986.134.3.526.
10
Comparison of dosages, intervals, and drugs in the prevention of Pneumocystis carinii pneumonia.预防卡氏肺孢子虫肺炎时不同剂量、给药间隔及药物的比较。
Antimicrob Agents Chemother. 1988 May;32(5):623-5. doi: 10.1128/AAC.32.5.623.

引用本文的文献

1
Inhibitors of folic acid synthesis in the treatment of experimental Pneumocystis carinii pneumonia.叶酸合成抑制剂在实验性卡氏肺孢子虫肺炎治疗中的应用
Antimicrob Agents Chemother. 1988 Jan;32(1):96-103. doi: 10.1128/AAC.32.1.96.
2
Improved rat model for studying Pneumocystis carinii pneumonia.用于研究卡氏肺孢子虫肺炎的改良大鼠模型。
J Clin Microbiol. 1987 Mar;25(3):480-4. doi: 10.1128/jcm.25.3.480-484.1987.
3
Treatment of experimental pneumocystosis: review of 7 years of experience and development of a new system for classifying antimicrobial drugs.实验性肺孢子菌病的治疗：七年经验回顾及抗菌药物分类新系统的开发
Antimicrob Agents Chemother. 1992 Sep;36(9):1943-50. doi: 10.1128/AAC.36.9.1943.
4
Activities of antifolate, antiviral, and other drugs in an immunosuppressed rat model of Pneumocystis carinii pneumonia.抗叶酸、抗病毒及其他药物在卡氏肺孢子虫肺炎免疫抑制大鼠模型中的活性
Antimicrob Agents Chemother. 1992 Sep;36(9):1935-42. doi: 10.1128/AAC.36.9.1935.

本文引用的文献

1
THE TREATMENT OF TOXOPLASMA UVEITIS.弓形虫性葡萄膜炎的治疗
Am J Ophthalmol. 1964 Oct;58:611-6. doi: 10.1016/0002-9394(64)91378-9.
2
Neutropenia and thrombocytopenia in renal allograft recipients treated with trimethoprim-sulfamethoxazole.接受甲氧苄啶-磺胺甲恶唑治疗的肾移植受者出现中性粒细胞减少和血小板减少。
Ann Intern Med. 1980 Oct;93(4):560-2. doi: 10.7326/0003-4819-93-4-560.
3
Acute megaloblastic anemia induced by high-dose trimethoprim-sulfamethoxazole.高剂量甲氧苄啶-磺胺甲恶唑诱发的急性巨幼细胞贫血
Ann Intern Med. 1981 Jun;94(6):780-1. doi: 10.7326/0003-4819-94-6-780.
4
Trimethoprim-sulfamethoxazole for the treatment of Pneumocystis carinii pneumonia.甲氧苄啶-磺胺甲恶唑用于治疗卡氏肺孢子虫肺炎。
Ann Intern Med. 1980 Jun;92(6):762-9. doi: 10.7326/0003-4819-92-6-762.
5
The effect of trimethoprim/sulfamethoxazole on Friend erythroleukemia cells.甲氧苄啶/磺胺甲恶唑对弗氏红白血病细胞的作用。
Blood. 1980 Mar;55(3):501-4.
6
Resistance to trimethoprim-sulfamethoxazole in the treatment of Pneumocystis carinii pneumonia. Implication of folinic acid.甲氧苄啶-磺胺甲恶唑治疗卡氏肺孢子虫肺炎的耐药性。亚叶酸的影响。
Chest. 1984 Jul;86(1):149-50. doi: 10.1378/chest.86.1.149.
7
Intermittent chemoprophylaxis for Pneumocystis carinii pneumonia.卡氏肺孢子虫肺炎的间歇化学预防
Antimicrob Agents Chemother. 1983 Aug;24(2):300-1. doi: 10.1128/AAC.24.2.300.
8
Adverse reactions to trimethoprim-sulfamethoxazole in patients with the acquired immunodeficiency syndrome.获得性免疫缺陷综合征患者对甲氧苄啶-磺胺甲恶唑的不良反应。
Ann Intern Med. 1984 Apr;100(4):495-9. doi: 10.7326/0003-4819-100-4-495.
9
Effects of trimethoprim on folate metabolism in man.
Clin Pharmacol Ther. 1968 Sep-Oct;9(5):550-60. doi: 10.1002/cpt196895550.
10
Leucopenia associated with trimethoprim-sulphamethoxazole after renal transplantation.肾移植后与复方新诺明相关的白细胞减少症。
Br Med J. 1971 Sep 11;3(5775):610-2. doi: 10.1136/bmj.3.5775.610.